We showed that a peptide vaccine composed of liposome-encapsulated CpG-DNA and a B-cell epitope, predicted from the amino acid sequence of TM4SF5, contributed to prevention and therapy of HCC and colon cancer in a mouse model [7–9]. This evidence concerns the gene TM4SF5 and malignant colon neoplasm.